KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Non-Current Debt (2016 - 2025)

Biolife Solutions (BLFS) has disclosed Non-Current Debt for 12 consecutive years, with $2.5 million as the latest value for Q1 2025.

  • On a quarterly basis, Non-Current Debt fell 84.06% to $2.5 million in Q1 2025 year-over-year; TTM through Mar 2025 was $2.5 million, a 84.06% decrease, with the full-year FY2024 number at $5.0 million, down 71.54% from a year prior.
  • Non-Current Debt was $2.5 million for Q1 2025 at Biolife Solutions, down from $5.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $24.2 million in Q3 2022 to a low of $916000.0 in Q1 2021.
  • A 5-year average of $12.1 million and a median of $7.8 million in 2024 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: soared 869.92% in 2021, then plummeted 84.06% in 2025.
  • Biolife Solutions' Non-Current Debt stood at $6.4 million in 2021, then skyrocketed by 274.52% to $23.8 million in 2022, then fell by 26.19% to $17.6 million in 2023, then tumbled by 71.54% to $5.0 million in 2024, then plummeted by 49.99% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for BLFS's Non-Current Debt are $2.5 million (Q1 2025), $5.0 million (Q4 2024), and $7.8 million (Q3 2024).